{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:09:21Z","timestamp":1793758161311,"version":"4.6.1"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41574-025-01162-4","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T10:34:48Z","timestamp":1755858888000},"page":"743-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The role of bone in whole-body energy metabolism"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-9634","authenticated-orcid":false,"given":"Beata","family":"Lecka-Czernik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-8199","authenticated-orcid":false,"given":"Clifford J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-8205","authenticated-orcid":false,"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/(SICI)1520-6300(1999)11:2<167::AID-AJHB4>3.0.CO;2-G","volume":"11","author":"JP Clarys","year":"1999","unstructured":"Clarys, J. P. et al. Human body composition: a review of adult dissection data. Am. J. Hum. Biol. 11, 167\u2013174 (1999).","journal-title":"Am. J. Hum. Biol."},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cell.2015.05.029","volume":"161","author":"J Wei","year":"2015","unstructured":"Wei, J. et al. Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell 161, 1576\u20131591 (2015).","journal-title":"Cell"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41574-024-00969-x","volume":"20","author":"S Stegen","year":"2024","unstructured":"Stegen, S. & Carmeliet, G. Metabolic regulation of skeletal cell fate and function. Nat. Rev. Endocrinol. 20, 399\u2013413 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41413-024-00374-0","volume":"12","author":"JC Bertels","year":"2024","unstructured":"Bertels, J. C., He, G. & Long, F. Metabolic reprogramming in skeletal cell differentiation. Bone Res. 12, 57 (2024).","journal-title":"Bone Res."},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/er.2017-00064","volume":"38","author":"WC Lee","year":"2017","unstructured":"Lee, W. C., Guntur, A. R., Long, F. & Rosen, C. J. Energy metabolism of the osteoblast: implications for osteoporosis. Endocr. Rev. 38, 255\u2013266 (2017).","journal-title":"Endocr. Rev."},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.bonr.2022.101594","volume":"16","author":"R Sautchuk Jr.","year":"2022","unstructured":"Sautchuk, R. Jr. & Eliseev, R. A. Cell energy metabolism and bone formation. Bone Rep. 16, 101594 (2022).","journal-title":"Bone Rep."},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.cmet.2019.01.016","volume":"29","author":"Y Yu","year":"2019","unstructured":"Yu, Y. et al. Glutamine metabolism regulates proliferation and lineage allocation in skeletal stem cells. Cell Metab. 29, 966\u2013978 (2019).","journal-title":"Cell Metab."},{"key":"1162_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101640","volume":"17","author":"F Long","year":"2022","unstructured":"Long, F. Glucose metabolism in skeletal cells. Bone Rep. 17, 101640 (2022).","journal-title":"Bone Rep."},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1210\/en.2013-1974","volume":"155","author":"AR Guntur","year":"2014","unstructured":"Guntur, A. R., Le, P. T., Farber, C. R. & Rosen, C. J. Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology 155, 1589\u20131595 (2014).","journal-title":"Endocrinology"},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/scd.2015.0193","volume":"25","author":"LC Shum","year":"2016","unstructured":"Shum, L. C., White, N. S., Mills, B. N., Bentley, K. L. & Eliseev, R. A. Energy metabolism in mesenchymal stem cells during osteogenic differentiation. Stem Cell Dev. 25, 114\u2013122 (2016).","journal-title":"Stem Cell Dev."},{"key":"1162_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92704","volume":"2","author":"SP Kim","year":"2017","unstructured":"Kim, S. P. et al. Fatty acid oxidation by the osteoblast is required for normal bone acquisition in a sex- and diet-dependent manner. JCI Insight 2, e92704 (2017).","journal-title":"JCI Insight"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"997358","DOI":"10.3389\/fphys.2022.997358","volume":"13","author":"P Kushwaha","year":"2022","unstructured":"Kushwaha, P. et al. Mitochondrial fatty acid beta-oxidation is important for normal osteoclast formation in growing female mice. Front. Physiol. 13, 997358 (2022).","journal-title":"Front. Physiol."},{"key":"1162_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14285-1","volume":"11","author":"JS Brunner","year":"2020","unstructured":"Brunner, J. S. et al. Environmental arginine controls multinuclear giant cell metabolism and formation. Nat. Commun. 11, 431 (2020).","journal-title":"Nat. Commun."},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/ard-2022-223626","volume":"83","author":"S Cao","year":"2024","unstructured":"Cao, S. et al. l-arginine metabolism inhibits arthritis and inflammatory bone loss. Ann. Rheum. Dis. 83, 72\u201387 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1162_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s42255-023-00948-y","volume":"6","author":"S Stegen","year":"2024","unstructured":"Stegen, S., Moermans, K., Stockmans, I., Thienpont, B. & Carmeliet, G. The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression. Nat. Metab. 6, 141\u2013152 (2024).","journal-title":"Nat. Metab."},{"key":"1162_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","volume":"82","author":"AG Robling","year":"2020","unstructured":"Robling, A. G. & Bonewald, L. F. The osteocyte: new insights. Annu. Rev. Physiol. 82, 485\u2013506 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2015.02.016","volume":"75","author":"PR Buenzli","year":"2015","unstructured":"Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human skeleton. Bone 75, 144\u2013150 (2015).","journal-title":"Bone"},{"key":"1162_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1073\/pnas.1715687114","volume":"115","author":"JO Jansson","year":"2018","unstructured":"Jansson, J. O. et al. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc. Natl Acad. Sci. USA 115, 427\u2013432 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR19","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2022.0219","volume":"378","author":"JO Jansson","year":"2023","unstructured":"Jansson, J. O. et al. The dual hypothesis of homeostatic body weight regulation, including gravity-dependent and leptin-dependent actions. Philos. Trans. R. Soc. Lond. B Biol. Sci. 378, 20220219 (2023).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1162_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100338","volume":"22","author":"C Ohlsson","year":"2020","unstructured":"Ohlsson, C. et al. Increased weight loading reduces body weight and body fat in obese subjects \u2014 a proof of concept randomized clinical trial. eClinicalMedicine 22, 100338 (2020).","journal-title":"eClinicalMedicine"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1210\/clinem\/dgae344","volume":"109","author":"J Bellman","year":"2024","unstructured":"Bellman, J. et al. Loading enhances glucose uptake in muscles, bones, and bone marrow of lower extremities in humans. J. Clin. Endocrinol. Metab. 109, 3126\u20133136 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11914-019-00500-6","volume":"17","author":"CE Yellowley","year":"2019","unstructured":"Yellowley, C. E. & Genetos, D. C. Hypoxia signaling in the skeleton: implications for bone health. Curr. Osteoporos. Rep. 17, 26\u201335 (2019).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102000","volume":"88","author":"S Baroi","year":"2024","unstructured":"Baroi, S. et al. PPARG in osteocytes controls cell bioenergetics and systemic energy metabolism independently of sclerostin levels in circulation. Mol. Metab. 88, 102000 (2024).","journal-title":"Mol. Metab."},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1210\/en.2016-1583","volume":"157","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Glucose transporter-4 facilitates insulin-stimulated glucose uptake in osteoblasts. Endocrinology 157, 4094\u20134103 (2016).","journal-title":"Endocrinology"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cell.2010.06.002","volume":"142","author":"K Fulzele","year":"2010","unstructured":"Fulzele, K. et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309\u2013319 (2010).","journal-title":"Cell"},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","volume":"142","author":"M Ferron","year":"2010","unstructured":"Ferron, M. et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142, 296\u2013308 (2010).","journal-title":"Cell"},{"key":"1162_CR27","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1210\/endo.140.4.6620","volume":"140","author":"G Maor","year":"1999","unstructured":"Maor, G. & Karnieli, E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 140, 1841\u20131851 (1999).","journal-title":"Endocrinology"},{"key":"1162_CR28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/jbmr.5650110916","volume":"11","author":"DM Thomas","year":"1996","unstructured":"Thomas, D. M., Hards, D. K., Rogers, S. D., Ng, K. W. & Best, J. D. Insulin receptor expression in bone. J. Bone Min. Res. 11, 1312\u20131320 (1996).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/703589","volume":"2014","author":"K Thrailkill","year":"2014","unstructured":"Thrailkill, K. et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. J. Diabetes Res. 2014, 703589 (2014).","journal-title":"J. Diabetes Res."},{"key":"1162_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65717-3","volume":"10","author":"JL Fowlkes","year":"2020","unstructured":"Fowlkes, J. L. et al. Postnatal loss of the insulin receptor in osteoprogenitor cells does not impart a metabolic phenotype. Sci. Rep. 10, 8842 (2020).","journal-title":"Sci. Rep."},{"key":"1162_CR31","doi-asserted-by":"publisher","first-page":"25649","DOI":"10.1074\/jbc.M700651200","volume":"282","author":"K Fulzele","year":"2007","unstructured":"Fulzele, K. et al. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282, 25649\u201325658 (2007).","journal-title":"J. Biol. Chem."},{"key":"1162_CR32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/db16-0063","volume":"65","author":"DE Sellmeyer","year":"2016","unstructured":"Sellmeyer, D. E. et al. Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes 65, 1757\u20131766 (2016).","journal-title":"Diabetes"},{"key":"1162_CR33","doi-asserted-by":"publisher","first-page":"16004","DOI":"10.1038\/boneres.2016.4","volume":"4","author":"ML Zoch","year":"2016","unstructured":"Zoch, M. L., Abou, D. S., Clemens, T. L., Thorek, D. L. & Riddle, R. C. In vivo radiometric analysis of glucose uptake and distribution in mouse bone. Bone Res. 4, 16004 (2016).","journal-title":"Bone Res."},{"key":"1162_CR34","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.2337\/db17-0116","volume":"66","author":"J Brun","year":"2017","unstructured":"Brun, J. et al. Bone regulates browning and energy metabolism through mature osteoblast\/osteocyte PPARgamma expression. Diabetes 66, 2541\u20132554 (2017).","journal-title":"Diabetes"},{"key":"1162_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145467","volume":"14","author":"A Chougule","year":"2023","unstructured":"Chougule, A. et al. Osteocytes contribute via nuclear receptor PPAR-alpha to maintenance of bone and systemic energy metabolism. Front. Endocrinol. 14, 1145467 (2023).","journal-title":"Front. Endocrinol."},{"key":"1162_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1113\/JP280572","volume":"599","author":"SJ Kierans","year":"2021","unstructured":"Kierans, S. J. & Taylor, C. T. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J. Physiol. 599, 23\u201337 (2021).","journal-title":"J. Physiol."},{"key":"1162_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrrheum.2012.36","volume":"8","author":"C Maes","year":"2012","unstructured":"Maes, C., Carmeliet, G. & Schipani, E. Hypoxia-driven pathways in bone development, regeneration and disease. Nat. Rev. Rheumatol. 8, 358\u2013366 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1162_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bone.2018.08.022","volume":"116","author":"GG Loots","year":"2018","unstructured":"Loots, G. G. et al. Vhl deficiency in osteocytes produces high bone mass and hematopoietic defects. Bone 116, 307\u2013314 (2018).","journal-title":"Bone"},{"key":"1162_CR39","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.1324290111","volume":"111","author":"JN Regan","year":"2014","unstructured":"Regan, J. N. et al. Up-regulation of glycolytic metabolism is required for HIF1alpha-driven bone formation. Proc. Natl Acad. Sci. USA 111, 8673\u20138678 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR40","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1172\/JCI97794","volume":"128","author":"N Dirckx","year":"2018","unstructured":"Dirckx, N. et al. Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism. J. Clin. Invest. 128, 1087\u20131105 (2018).","journal-title":"J. Clin. Invest."},{"key":"1162_CR41","doi-asserted-by":"publisher","first-page":"770705","DOI":"10.3389\/fcell.2021.770705","volume":"9","author":"L Wang","year":"2021","unstructured":"Wang, L., Zhang, H., Wang, S., Chen, X. & Su, J. Bone marrow adipocytes: a critical player in the bone marrow microenvironment. Front. Cell Dev. Biol. 9, 770705 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1162_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/nu13051412","volume":"13","author":"K Piotrowska","year":"2021","unstructured":"Piotrowska, K. & Tarnowski, M. Bone marrow adipocytes \u2014 role in physiology and various nutritional conditions in human and animal models. Nutrients 13, 1412 (2021).","journal-title":"Nutrients"},{"key":"1162_CR43","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cmet.2014.06.003","volume":"20","author":"WP Cawthorn","year":"2014","unstructured":"Cawthorn, W. P. et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 20, 368\u2013375 (2014).","journal-title":"Cell Metab."},{"key":"1162_CR44","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/jbmr.3408","volume":"33","author":"M Tencerova","year":"2018","unstructured":"Tencerova, M. et al. High-fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice. J. Bone Min. Res. 33, 1154\u20131165 (2018).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11914-019-00552-8","volume":"17","author":"M Tencerova","year":"2019","unstructured":"Tencerova, M., Okla, M. & Kassem, M. Insulin signaling in bone marrow adipocytes. Curr. Osteoporos. Rep. 17, 446\u2013454 (2019).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16878-2","volume":"11","author":"KJ Suchacki","year":"2020","unstructured":"Suchacki, K. J. et al. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. Nat. Commun. 11, 3097 (2020).","journal-title":"Nat. Commun."},{"key":"1162_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41574-023-00879-4","volume":"19","author":"CJ Rosen","year":"2023","unstructured":"Rosen, C. J. & Horowitz, M. C. Nutrient regulation of bone marrow adipose tissue: skeletal implications of weight loss. Nat. Rev. Endocrinol. 19, 626\u2013638 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1162_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fendo.2017.00188","volume":"8","author":"B Lecka-Czernik","year":"2017","unstructured":"Lecka-Czernik, B. et al. Marrow adipose tissue: skeletal location, sexual dimorphism, and response to sex steroid deficiency. Front. Endocrinol. 8, 188 (2017).","journal-title":"Front. Endocrinol."},{"key":"1162_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11914-022-00765-4","volume":"21","author":"B Bermudez","year":"2023","unstructured":"Bermudez, B., Ishii, T., Wu, Y. H., Carpenter, R. D. & Sherk, V. D. Energy balance and bone health: a nutrient availability perspective. Curr. Osteoporos. Rep. 21, 77\u201384 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138636","volume":"6","author":"PK Fazeli","year":"2021","unstructured":"Fazeli, P. K. et al. The dynamics of human bone marrow adipose tissue in response to feeding and fasting. JCI Insight 6, e138636 (2021).","journal-title":"JCI Insight"},{"key":"1162_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1591280","volume":"16","author":"SN Costa","year":"2025","unstructured":"Costa, S. N. et al. Altered metabolomics and inflammatory transcriptomics in human bone marrow adipocytes after acute high calorie diet and acute fasting. Front. Endocrinol. 16, 1591280 (2025).","journal-title":"Front. Endocrinol."},{"key":"1162_CR52","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/jcp.24954","volume":"230","author":"CR Doucette","year":"2015","unstructured":"Doucette, C. R. et al. A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL\/6J mice. J. Cell Physiol. 230, 2032\u20132037 (2015).","journal-title":"J. Cell Physiol."},{"key":"1162_CR53","first-page":"1188","volume":"39","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Calorie restriction in mice impairs cortical but not trabecular peak bone mass by suppressing bone remodeling. J. Bone Min. Res. 39, 1188\u20131199 (2024).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR54","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1210\/jc.2008-2532","volume":"94","author":"MA Bredella","year":"2009","unstructured":"Bredella, M. A. et al. Increased bone marrow fat in anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 2129\u20132136 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR55","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78496","volume":"11","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Lipolysis of bone marrow adipocytes is required to fuel bone and the marrow niche during energy deficits. eLife 11, e78496 (2022).","journal-title":"eLife"},{"key":"1162_CR56","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1096\/fj.201800948RR","volume":"33","author":"DE Maridas","year":"2019","unstructured":"Maridas, D. E. et al. Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton. FASEB J. 33, 2885\u20132898 (2019).","journal-title":"FASEB J."},{"key":"1162_CR57","doi-asserted-by":"publisher","first-page":"101480","DOI":"10.1016\/j.molmet.2022.101480","volume":"60","author":"E Rendina-Ruedy","year":"2022","unstructured":"Rendina-Ruedy, E. & Rosen, C. J. Parathyroid hormone (PTH) regulation of metabolic homeostasis: an old dog teaches us new tricks. Mol. Metab. 60, 101480 (2022).","journal-title":"Mol. Metab."},{"key":"1162_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41413-023-00297-2","volume":"11","author":"A Nandy","year":"2023","unstructured":"Nandy, A. et al. Lipolysis supports bone formation by providing osteoblasts with endogenous fatty acid substrates to maintain bioenergetic status. Bone Res. 11, 62 (2023).","journal-title":"Bone Res."},{"key":"1162_CR59","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456\u2013469 (2007).","journal-title":"Cell"},{"key":"1162_CR60","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00125-011-2155-z","volume":"54","author":"P Ducy","year":"2011","unstructured":"Ducy, P. The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia 54, 1291\u20131297 (2011).","journal-title":"Diabetologia"},{"key":"1162_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/nu10070847","volume":"10","author":"X Lin","year":"2018","unstructured":"Lin, X., Brennan-Speranza, T. C., Levinger, I. & Yeap, B. B. Undercarboxylated osteocalcin: experimental and human evidence for a role in glucose homeostasis and muscle regulation of insulin sensitivity. Nutrients 10, 847 (2018).","journal-title":"Nutrients"},{"key":"1162_CR62","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41401-019-0311-z","volume":"41","author":"XL Zhang","year":"2020","unstructured":"Zhang, X. L. et al. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway. Acta Pharmacol. Sin. 41, 383\u2013393 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"1162_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008361","volume":"16","author":"CR Diegel","year":"2020","unstructured":"Diegel, C. R. et al. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet. 16, e1008361 (2020).","journal-title":"PLoS Genet."},{"key":"1162_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008586","volume":"16","author":"T Moriishi","year":"2020","unstructured":"Moriishi, T. et al. Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet. 16, e1008586 (2020).","journal-title":"PLoS Genet."},{"key":"1162_CR65","doi-asserted-by":"publisher","first-page":"584147","DOI":"10.3389\/fendo.2021.584147","volume":"12","author":"JS Wang","year":"2021","unstructured":"Wang, J. S., Mazur, C. M. & Wein, M. N. Sclerostin and osteocalcin: candidate bone-produced hormones. Front. Endocrinol. 12, 584147 (2021).","journal-title":"Front. Endocrinol."},{"key":"1162_CR66","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1530\/EJE-16-0652","volume":"176","author":"K Hygum","year":"2017","unstructured":"Hygum, K., Starup-Linde, J., Harslof, T., Vestergaard, P. & Langdahl, B. L. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover \u2014 a systematic review and meta-analysis. Eur. J. Endocrinol. 176, R137\u2013R157 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"1162_CR67","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/jbmr.4140","volume":"35","author":"N Napoli","year":"2020","unstructured":"Napoli, N. et al. Bone turnover markers do not predict fracture risk in type 2 diabetes. J. Bone Min. Res. 35, 2363\u20132371 (2020).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1210\/jc.2008-1455","volume":"94","author":"I Kanazawa","year":"2009","unstructured":"Kanazawa, I. et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 45\u201349 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR69","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40618-014-0092-7","volume":"37","author":"E Maddaloni","year":"2014","unstructured":"Maddaloni, E. et al. Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes. J. Endocrinol. Invest. 37, 661\u2013666 (2014).","journal-title":"J. Endocrinol. Invest."},{"key":"1162_CR70","doi-asserted-by":"publisher","first-page":"E1982","DOI":"10.1210\/jc.2011-0587","volume":"96","author":"AL Schafer","year":"2011","unstructured":"Schafer, A. L. et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1\u201384) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J. Clin. Endocrinol. Metab. 96, E1982\u2013E1989 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR71","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","volume":"55","author":"AT Turer","year":"2012","unstructured":"Turer, A. T. & Scherer, P. E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 55, 2319\u20132326 (2012).","journal-title":"Diabetologia"},{"key":"1162_CR72","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/jbmr.1865","volume":"28","author":"AV Schwartz","year":"2013","unstructured":"Schwartz, A. V. et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J. Bone Min. Res. 28, 1348\u20131354 (2013).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR73","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jbmr.4519","volume":"37","author":"ME Babey","year":"2022","unstructured":"Babey, M. E. et al. No evidence of association between undercarboxylated osteocalcin and incident type 2 diabetes. J. Bone Min. Res. 37, 876\u2013884 (2022).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","volume":"12","author":"L Hu","year":"2024","unstructured":"Hu, L., Chen, W., Qian, A. & Li, Y. P. Wnt\/beta-catenin signaling components and mechanisms in bone formation, homeostasis, and disease. Bone Res. 12, 39 (2024).","journal-title":"Bone Res."},{"key":"1162_CR75","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/jcb.25432","volume":"117","author":"M Ukita","year":"2016","unstructured":"Ukita, M., Yamaguchi, T., Ohata, N. & Tamura, M. Sclerostin enhances adipocyte differentiation in 3T3-L1 cells. J. Cell Biochem. 117, 1419\u20131428 (2016).","journal-title":"J. Cell Biochem."},{"key":"1162_CR76","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/jcp.25976","volume":"233","author":"H Fairfield","year":"2018","unstructured":"Fairfield, H. et al. The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. J. Cell Physiol. 233, 1156\u20131167 (2018).","journal-title":"J. Cell Physiol."},{"key":"1162_CR77","doi-asserted-by":"publisher","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","volume":"114","author":"SP Kim","year":"2017","unstructured":"Kim, S. P. et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl Acad. Sci. USA 114, E11238\u2013E11247 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR78","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/jbmr.4303","volume":"36","author":"G Leanza","year":"2021","unstructured":"Leanza, G. et al. Gain-of-function Lrp5 mutation improves bone mass and strength and delays hyperglycemia in a mouse model of insulin-deficient diabetes. J. Bone Min. Res. 36, 1403\u20131415 (2021).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR79","doi-asserted-by":"publisher","first-page":"115913","DOI":"10.1016\/j.bone.2021.115913","volume":"147","author":"S Baroi","year":"2021","unstructured":"Baroi, S., Czernik, P. J., Chougule, A., Griffin, P. R. & Lecka-Czernik, B. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss. Bone 147, 115913 (2021).","journal-title":"Bone"},{"key":"1162_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106999","volume":"26","author":"SP Kim","year":"2023","unstructured":"Kim, S. P. et al. Peroxisome proliferator activated receptor-gamma in osteoblasts controls bone formation and fat mass by regulating sclerostin expression. iScience 26, 106999 (2023).","journal-title":"iScience"},{"key":"1162_CR81","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/dc14-2989","volume":"38","author":"G Daniele","year":"2015","unstructured":"Daniele, G. et al. Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care 38, 1509\u20131517 (2015).","journal-title":"Diabetes Care"},{"key":"1162_CR82","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garcia-Martin","year":"2012","unstructured":"Garcia-Martin, A. et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 234\u2013241 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR83","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1210\/jc.2012-1901","volume":"97","author":"A Gaudio","year":"2012","unstructured":"Gaudio, A. et al. Sclerostin levels associated with inhibition of the Wnt\/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 3744\u20133750 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR84","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1210\/jc.2017-02274","volume":"103","author":"N Napoli","year":"2018","unstructured":"Napoli, N. et al. Serum sclerostin and bone turnover in latent autoimmune diabetes in adults. J. Clin. Endocrinol. Metab. 103, 1921\u20131928 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR85","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1210\/jc.2011-2958","volume":"97","author":"L Gennari","year":"2012","unstructured":"Gennari, L. et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1737\u20131744 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrendo.2011.233","volume":"8","author":"C Hamann","year":"2012","unstructured":"Hamann, C., Kirschner, S., Gunther, K. P. & Hofbauer, L. C. Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nat. Rev. Endocrinol. 8, 297\u2013305 (2012).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1162_CR87","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/jbmr.4153","volume":"35","author":"A Piccoli","year":"2020","unstructured":"Piccoli, A. et al. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J. Bone Min. Res. 35, 2415\u20132422 (2020).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR88","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.90437.3","volume":"12","author":"G Leanza","year":"2024","unstructured":"Leanza, G. et al. Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength. eLife 12, RP90437 (2024).","journal-title":"eLife"},{"key":"1162_CR89","doi-asserted-by":"publisher","first-page":"E2584","DOI":"10.1210\/jc.2013-4493","volume":"99","author":"YH Ma","year":"2014","unstructured":"Ma, Y. H. et al. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J. Clin. Endocrinol. Metab. 99, E2584\u2013E2590 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR90","doi-asserted-by":"publisher","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","volume":"97","author":"T Urano","year":"2012","unstructured":"Urano, T., Shiraki, M., Ouchi, Y. & Inoue, S. Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J. Clin. Endocrinol. Metab. 97, E1473\u2013E1477 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR91","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","volume":"76","author":"Z Sheng","year":"2012","unstructured":"Sheng, Z. et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin. Endocrinol. 76, 797\u2013801 (2012).","journal-title":"Clin. Endocrinol."},{"key":"1162_CR92","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.3390\/ijms24065922","volume":"24","author":"M Courtalin","year":"2023","unstructured":"Courtalin, M. et al. Relationships between circulating sclerostin, bone marrow adiposity, other adipose deposits and lean mass in post-menopausal women. Int. J. Mol. Sci. 24, 5922 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1162_CR93","doi-asserted-by":"publisher","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn, J. et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 12, eaay6570 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1162_CR94","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jbmr.4287","volume":"36","author":"G Holdsworth","year":"2021","unstructured":"Holdsworth, G. et al. Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans. J. Bone Min. Res. 36, 1326\u20131339 (2021).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR95","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/art.42538","volume":"75","author":"J Zheng","year":"2023","unstructured":"Zheng, J. et al. Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by mendelian randomization. Arthritis Rheumatol. 75, 1781\u20131792 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1162_CR96","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-023-00810-w","volume":"21","author":"JH Tobias","year":"2023","unstructured":"Tobias, J. H. Sclerostin and cardiovascular disease. Curr. Osteoporos. Rep. 21, 519\u2013526 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51155-6","volume":"15","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Bone controls browning of white adipose tissue and protects from diet-induced obesity through Schnurri-3-regulated SLIT2 secretion. Nat. Commun. 15, 6697 (2024).","journal-title":"Nat. Commun."},{"key":"1162_CR98","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/JME-20-0178","volume":"66","author":"BB Ho","year":"2021","unstructured":"Ho, B. B. & Bergwitz, C. FGF23 signalling and physiology. J. Mol. Endocrinol. 66, R23\u2013R32 (2021).","journal-title":"J. Mol. Endocrinol."},{"key":"1162_CR99","doi-asserted-by":"publisher","first-page":"e971","DOI":"10.1210\/clinem\/dgad246","volume":"108","author":"A van der Vaart","year":"2023","unstructured":"van der Vaart, A. et al. Fibroblast growth factor 23, glucose homeostasis, and incident diabetes: findings of 2 cohort studies. J. Clin. Endocrinol. Metab. 108, e971\u2013e978 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1162_CR100","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.1800160115","volume":"115","author":"L Bar","year":"2018","unstructured":"Bar, L. et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc. Natl Acad. Sci. USA 115, 5804\u20135809 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR101","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41413-021-00142-4","volume":"9","author":"R Zhou","year":"2021","unstructured":"Zhou, R. et al. Endocrine role of bone in the regulation of energy metabolism. Bone Res. 9, 25 (2021).","journal-title":"Bone Res."},{"key":"1162_CR102","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI131190","volume":"130","author":"P Simic","year":"2020","unstructured":"Simic, P. et al. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J. Clin. Invest. 130, 1513\u20131526 (2020).","journal-title":"J. Clin. Invest."},{"key":"1162_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164610","volume":"133","author":"W Zhou","year":"2023","unstructured":"Zhou, W. et al. Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis. J. Clin. Invest. 133, e164610 (2023).","journal-title":"J. Clin. Invest."},{"key":"1162_CR104","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae141","volume":"165","author":"MY Park","year":"2024","unstructured":"Park, M. Y. et al. Targeted deletion of fibroblast growth factor-23 rescues metabolic dysregulation of diet-induced obesity in female mice. Endocrinology 165, bqae141 (2024).","journal-title":"Endocrinology"},{"key":"1162_CR105","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/cen.13981","volume":"91","author":"EO Billington","year":"2019","unstructured":"Billington, E. O. et al. Fibroblast growth factor 23 levels decline following sleeve gastrectomy. Clin. Endocrinol. 91, 87\u201393 (2019).","journal-title":"Clin. Endocrinol."},{"key":"1162_CR106","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0026-0495(76)90083-4","volume":"25","author":"TK Sinha","year":"1976","unstructured":"Sinha, T. K., Thajchayapong, P., Queener, S. F., Allen, D. O. & Bell, N. H. On the lipolytic action of parathyroid hormone in man. Metabolism 25, 251\u2013260 (1976).","journal-title":"Metabolism"},{"key":"1162_CR107","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165604","volume":"8","author":"NS Alekos","year":"2023","unstructured":"Alekos, N. S. et al. Mitochondrial beta-oxidation of adipose-derived fatty acids by osteoblasts fuels parathyroid hormone-induced bone formation. JCI Insight 8, e165604 (2023).","journal-title":"JCI Insight"},{"key":"1162_CR108","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cmet.2017.01.001","volume":"25","author":"Y Fan","year":"2017","unstructured":"Fan, Y. et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab. 25, 661\u2013672 (2017).","journal-title":"Cell Metab."},{"key":"1162_CR109","doi-asserted-by":"publisher","first-page":"167","DOI":"10.31083\/j.fbl2808167","volume":"28","author":"P Srisuwarn","year":"2023","unstructured":"Srisuwarn, P. & Disthabanchong, S. Role of parathyroid hormone and parathyroid hormone-related protein in protein-energy malnutrition. Front. Biosci. 28, 167 (2023).","journal-title":"Front. Biosci."},{"key":"1162_CR110","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jbmr\/zjae056","volume":"39","author":"YK Tay Donovan","year":"2024","unstructured":"Tay Donovan, Y. K. & Bilezikian, J. P. Interactions between PTH and adiposity: appetizing possibilities. J. Bone Min. Res. 39, 536\u2013543 (2024).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR111","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83345","volume":"12","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. PTH regulates osteogenesis and suppresses adipogenesis through Zfp467 in a feed-forward, PTH1R-cyclic AMP-dependent manner. elife 12, e83345 (2023).","journal-title":"elife"},{"key":"1162_CR112","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ebiom.2018.11.057","volume":"40","author":"Y He","year":"2019","unstructured":"He, Y. et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism. eBioMedicine 40, 56\u201366 (2019).","journal-title":"eBioMedicine"},{"key":"1162_CR113","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fendo.2015.00028","volume":"6","author":"JS On","year":"2015","unstructured":"On, J. S., Chow, B. K. & Lee, L. T. Evolution of parathyroid hormone receptor family and their ligands in vertebrate. Front. Endocrinol. 6, 28 (2015).","journal-title":"Front. Endocrinol."},{"key":"1162_CR114","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00198-013-2313-x","volume":"24","author":"Y Abu-Amer","year":"2013","unstructured":"Abu-Amer, Y. NF-kappaB signaling and bone resorption. Osteoporos. Int. 24, 2377\u20132386 (2013).","journal-title":"Osteoporos. Int."},{"key":"1162_CR115","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal. Transduct. Target. Ther. 2, 17023 (2017).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1162_CR116","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","volume":"11","author":"D Cai","year":"2005","unstructured":"Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183\u2013190 (2005).","journal-title":"Nat. Med."},{"key":"1162_CR117","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms25158242","volume":"25","author":"MLE Michalani","year":"2024","unstructured":"Michalani, M. L. E., Passarelli, M. & Machado, U. F. Nuclear factor-kappa-B mediates the advanced glycation end product-induced repression of slc2a4 gene expression in 3T3-L1 adipocytes. Int. J. Mol. Sci. 25, 8242 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1162_CR118","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1530\/JME-16-0183","volume":"61","author":"K Meyerovich","year":"2018","unstructured":"Meyerovich, K., Ortis, F. & Cardozo, A. K. The non-canonical NF-kappaB pathway and its contribution to beta-cell failure in diabetes. J. Mol. Endocrinol. 61, F1\u2013F6 (2018).","journal-title":"J. Mol. Endocrinol."},{"key":"1162_CR119","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmet.2015.05.021","volume":"22","author":"NG Kondegowda","year":"2015","unstructured":"Kondegowda, N. G. et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-kappaB ligand pathway. Cell Metab. 22, 77\u201385 (2015).","journal-title":"Cell Metab."},{"key":"1162_CR120","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14003-6","volume":"11","author":"MM Weivoda","year":"2020","unstructured":"Weivoda, M. M. et al. Identification of osteoclast\u2013osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat. Commun. 11, 87 (2020).","journal-title":"Nat. Commun."},{"key":"1162_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2991","volume":"34","author":"N Napoli","year":"2018","unstructured":"Napoli, N. et al. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab. Res. Rev. 34, e2991 (2018).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"1162_CR123","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.3390\/ijms241210289","volume":"24","author":"SC Lin","year":"2023","unstructured":"Lin, S. C. et al. Denosumab attenuates glucolipotoxicity-induced beta-cell dysfunction and apoptosis by attenuating RANK\/RANKL signals. Int. J. Mol. Sci. 24, 10289 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1162_CR124","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54734","volume":"7","author":"HK Huang","year":"2024","unstructured":"Huang, H. K. et al. Denosumab and the risk of diabetes in patients treated for osteoporosis. JAMA Netw. Open 7, e2354734 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1162_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073435","volume":"381","author":"H Lyu","year":"2023","unstructured":"Lyu, H. et al. Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ 381, e073435 (2023).","journal-title":"BMJ"},{"key":"1162_CR126","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00198-024-07182-6","volume":"35","author":"W Rathmann","year":"2024","unstructured":"Rathmann, W. & Kostev, K. Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. Osteoporos. Int. 35, 2099\u20132106 (2024).","journal-title":"Osteoporos. Int."},{"key":"1162_CR127","doi-asserted-by":"publisher","first-page":"115467","DOI":"10.1016\/j.bone.2020.115467","volume":"138","author":"J Yang","year":"2020","unstructured":"Yang, J., Ueharu, H. & Mishina, Y. Energy metabolism: a newly emerging target of BMP signaling in bone homeostasis. Bone 138, 115467 (2020).","journal-title":"Bone"},{"key":"1162_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10486","volume":"5","author":"P Tangseefa","year":"2021","unstructured":"Tangseefa, P. et al. Deletion of Rptor in preosteoblasts reveals a role for the mammalian target of rapamycin complex 1 (mTORC1) complex in dietary-induced changes to bone mass and glucose homeostasis in female mice. JBMR Plus 5, e10486 (2021).","journal-title":"JBMR Plus"},{"key":"1162_CR129","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41413-020-00123-z","volume":"9","author":"P Tangseefa","year":"2021","unstructured":"Tangseefa, P. et al. The mTORC1 complex in pre-osteoblasts regulates whole-body energy metabolism independently of osteocalcin. Bone Res. 9, 10 (2021).","journal-title":"Bone Res."},{"key":"1162_CR130","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1128\/MCB.01343-14","volume":"35","author":"JL Frey","year":"2015","unstructured":"Frey, J. L. et al. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Mol. Cell Biol. 35, 1979\u20131991 (2015).","journal-title":"Mol. Cell Biol."},{"key":"1162_CR131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","volume":"15","author":"I Chiodini","year":"2020","unstructured":"Chiodini, I., Falchetti, A., Merlotti, D., Eller Vainicher, C. & Gennari, L. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Exp. Rev. Endocrinol. Metab. 15, 283\u2013298 (2020).","journal-title":"Exp. Rev. Endocrinol. Metab."},{"key":"1162_CR132","doi-asserted-by":"publisher","first-page":"44326","DOI":"10.1074\/jbc.M111.283481","volume":"286","author":"M Almeida","year":"2011","unstructured":"Almeida, M., Han, L., Ambrogini, E., Weinstein, R. S. & Manolagas, S. C. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J. Biol. Chem. 286, 44326\u201344335 (2011).","journal-title":"J. Biol. Chem."},{"key":"1162_CR133","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti, G. & Giustina, A. Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol. 9, 265\u2013276 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1162_CR134","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11914-014-0197-0","volume":"12","author":"N Guanabens","year":"2014","unstructured":"Guanabens, N., Gifre, L. & Peris, P. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Curr. Osteoporos. Rep. 12, 90\u201397 (2014).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR135","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41413-021-00159-9","volume":"9","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. Osteoblastic glucocorticoid signaling exacerbates high-fat-diet-induced bone loss and obesity. Bone Res. 9, 40 (2021).","journal-title":"Bone Res."},{"key":"1162_CR136","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","volume":"44","author":"R Pofi","year":"2023","unstructured":"Pofi, R., Caratti, G., Ray, D. W. & Tomlinson, J. W. Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad? Endocr. Rev. 44, 975\u20131011 (2023).","journal-title":"Endocr. Rev."},{"key":"1162_CR137","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1172\/JCI63377","volume":"122","author":"TC Brennan-Speranza","year":"2012","unstructured":"Brennan-Speranza, T. C. et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J. Clin. Invest. 122, 4172\u20134189 (2012).","journal-title":"J. Clin. Invest."},{"key":"1162_CR138","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jbmr.4468","volume":"37","author":"JL Pierce","year":"2022","unstructured":"Pierce, J. L. et al. The glucocorticoid receptor in osterix-expressing cells regulates bone mass, bone marrow adipose tissue, and systemic metabolism in female mice during aging. J. Bone Min. Res. 37, 285\u2013302 (2022).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10202","volume":"3","author":"S Dillon","year":"2019","unstructured":"Dillon, S., Staines, K. A., Millan, J. L. & Farquharson, C. How to build a bone: PHOSPHO1, biomineralization, and beyond. JBMR Plus 3, e10202 (2019).","journal-title":"JBMR Plus"},{"key":"1162_CR140","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fendo.2018.00744","volume":"9","author":"T Willmer","year":"2018","unstructured":"Willmer, T., Johnson, R., Louw, J. & Pheiffer, C. Blood-based DNA methylation biomarkers for type 2 diabetes: potential for clinical applications. Front. Endocrinol. 9, 744 (2018).","journal-title":"Front. Endocrinol."},{"key":"1162_CR141","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1074\/jbc.M112.415117","volume":"288","author":"G Wu","year":"2013","unstructured":"Wu, G. et al. Choline supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferase-deficient mice via increased glucagon action. J. Biol. Chem. 288, 837\u2013847 (2013).","journal-title":"J. Biol. Chem."},{"key":"1162_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-00880-7","volume":"18","author":"KJ Suchacki","year":"2020","unstructured":"Suchacki, K. J. et al. PHOSPHO1 is a skeletal regulator of insulin resistance and obesity. BMC Biol. 18, 149 (2020).","journal-title":"BMC Biol."},{"key":"1162_CR143","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s42255-019-0041-z","volume":"1","author":"LG Straub","year":"2019","unstructured":"Straub, L. G. & Scherer, P. E. Metabolic messengers: adiponectin. Nat. Metab. 1, 334\u2013339 (2019).","journal-title":"Nat. Metab."},{"key":"1162_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-020-00122-0","volume":"9","author":"JW Lewis","year":"2021","unstructured":"Lewis, J. W., Edwards, J. R., Naylor, A. J. & McGettrick, H. M. Adiponectin signalling in bone homeostasis, with age and in disease. Bone Res. 9, 1 (2021).","journal-title":"Bone Res."},{"key":"1162_CR145","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82118","volume":"12","author":"K Inoue","year":"2023","unstructured":"Inoue, K. et al. Bone marrow Adipoq-lineage progenitors are a major cellular source of M-CSF that dominates bone marrow macrophage development, osteoclastogenesis, and bone mass. elife 12, e82118 (2023).","journal-title":"elife"},{"key":"1162_CR146","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bcpt.13332","volume":"127","author":"D Li","year":"2020","unstructured":"Li, D., Yan Sun, W., Fu, B., Xu, A. & Wang, Y. Lipocalin-2-the myth of its expression and function. Basic Clin. Pharmacol. Toxicol. 127, 142\u2013151 (2020).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"1162_CR147","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-nutr-071816-064559","volume":"37","author":"X Xiao","year":"2017","unstructured":"Xiao, X., Yeoh, B. S. & Vijay-Kumar, M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu. Rev. Nutr. 37, 103\u2013130 (2017).","journal-title":"Annu. Rev. Nutr."},{"key":"1162_CR148","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.mce.2016.03.011","volume":"427","author":"PG Kamble","year":"2016","unstructured":"Kamble, P. G. et al. Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue. Mol. Cell Endocrinol. 427, 124\u2013132 (2016).","journal-title":"Mol. Cell Endocrinol."},{"key":"1162_CR149","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jbmr.3406","volume":"33","author":"M Capulli","year":"2018","unstructured":"Capulli, M. et al. A complex role for lipocalin 2 in bone metabolism: global ablation in mice induces osteopenia caused by an altered energy metabolism. J. Bone Min. Res. 33, 1141\u20131153 (2018).","journal-title":"J. Bone Min. Res."},{"key":"1162_CR150","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature21697","volume":"543","author":"I Mosialou","year":"2017","unstructured":"Mosialou, I. et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature 543, 385\u2013390 (2017).","journal-title":"Nature"},{"key":"1162_CR151","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","volume":"82","author":"C Meier","year":"2016","unstructured":"Meier, C., Schwartz, A. V., Egger, A. & Lecka-Czernik, B. Effects of diabetes drugs on the skeleton. Bone 82, 93\u2013100 (2016).","journal-title":"Bone"},{"key":"1162_CR152","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer, L. C. et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 10, 207\u2013220 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1162_CR153","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm.4208","volume":"22","author":"W Zou","year":"2016","unstructured":"Zou, W. et al. PPAR-gamma regulates pharmacological but not physiological or pathological osteoclast formation. Nat. Med. 22, 1203\u20131205 (2016).","journal-title":"Nat. Med."},{"key":"1162_CR154","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ebiom.2016.06.040","volume":"10","author":"LA Stechschulte","year":"2016","unstructured":"Stechschulte, L. A. et al. PPARG post-translational modifications regulate bone formation and bone resorption. eBioMedicine 10, 174\u2013184 (2016).","journal-title":"eBioMedicine"},{"key":"1162_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101598","volume":"65","author":"A Benova","year":"2022","unstructured":"Benova, A. et al. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones. Mol. Metab. 65, 101598 (2022).","journal-title":"Mol. Metab."},{"key":"1162_CR156","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bone.2010.12.003","volume":"48","author":"WG Jang","year":"2011","unstructured":"Jang, W. G. et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48, 885\u2013893 (2011).","journal-title":"Bone"},{"key":"1162_CR157","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/jcb.23206","volume":"112","author":"QG Mai","year":"2011","unstructured":"Mai, Q. G. et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J. Cell Biochem. 112, 2902\u20132909 (2011).","journal-title":"J. Cell Biochem."},{"key":"1162_CR158","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00223-021-00805-8","volume":"108","author":"AR Shaik","year":"2021","unstructured":"Shaik, A. R. et al. Metformin: is it the well wisher of bone beyond glycemic control in diabetes mellitus? Calcif. Tissue Int. 108, 693\u2013707 (2021).","journal-title":"Calcif. Tissue Int."},{"key":"1162_CR159","doi-asserted-by":"publisher","first-page":"112125","DOI":"10.1016\/j.diabres.2025.112125","volume":"223","author":"E Maddaloni","year":"2025","unstructured":"Maddaloni, E., Coleman, R. L. & Holman, R. R. Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis. Diabetes Res. Clin. Pract. 223, 112125 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1162_CR160","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11914-022-00740-z","volume":"20","author":"M Tanios","year":"2022","unstructured":"Tanios, M. et al. Diabetes and impaired fracture healing: a narrative review of recent literature. Curr. Osteoporos. Rep. 20, 229\u2013239 (2022).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1162_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10817","volume":"7","author":"R Viggers","year":"2023","unstructured":"Viggers, R., Rasmussen, N. H. & Vestergaard, P. Effects of incretin therapy on skeletal health in type 2 diabetes \u2014 a systematic review. JBMR Plus 7, e10817 (2023).","journal-title":"JBMR Plus"},{"key":"1162_CR162","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"1162_CR163","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","volume":"134","author":"A Amaro","year":"2022","unstructured":"Amaro, A., Sugimoto, D. & Wharton, S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad. Med. 134, 5\u201317 (2022).","journal-title":"Postgrad. Med."},{"key":"1162_CR164","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR165","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR166","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen, M. S. et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClinicalMedicine 72, 102624 (2024).","journal-title":"eClinicalMedicine"},{"key":"1162_CR167","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16775","volume":"7","author":"SBK Jensen","year":"2024","unstructured":"Jensen, S. B. K. et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw. Open 7, e2416775 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1162_CR168","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae053","volume":"8","author":"C Wilson","year":"2024","unstructured":"Wilson, C. et al. Diabetes increases risk of lumbar spinal fusion complications: association with altered structure of newly formed bone at the fusion site. JBMR Plus 8, ziae053 (2024).","journal-title":"JBMR Plus"},{"key":"1162_CR169","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/jcm10050996","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis, A. D. et al. The impact of antiosteoporotic drugs on glucose metabolism and fracture risk in diabetes: good or bad news? J. Clin. Med. 10, 996 (2021).","journal-title":"J. Clin. Med."},{"key":"1162_CR170","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird, S. T. et al. Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331, 491\u2013499 (2024).","journal-title":"JAMA"},{"key":"1162_CR171","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41413-023-00306-4","volume":"12","author":"YY Zhang","year":"2024","unstructured":"Zhang, Y. Y. et al. Insights and implications of sexual dimorphism in osteoporosis. Bone Res. 12, 8 (2024).","journal-title":"Bone Res."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01162-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01162-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T01:02:03Z","timestamp":1762822923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-025-01162-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":171,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1038\/s41574-025-01162-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"30 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the affiliations listed for Nicola Napoli were incomplete and a third affiliation was not included; the affiliations are now updated in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}